Foundation Medicine Inc (NASDAQ:FMI) Director Evan/ Fa Jones sold 6,500 shares of Foundation Medicine stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $60.66, for a total value of $394,290.00. Following the completion of the sale, the director now owns 19,652 shares of the company’s stock, valued at $1,192,090.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Foundation Medicine Inc (FMI) traded down $0.60 during mid-day trading on Thursday, reaching $58.30. The company’s stock had a trading volume of 306,400 shares, compared to its average volume of 232,342. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a 1-year low of $17.10 and a 1-year high of $70.75.
Foundation Medicine (NASDAQ:FMI) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.06) by $0.16. The firm had revenue of $42.66 million during the quarter, compared to the consensus estimate of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The company’s quarterly revenue was up 45.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.90) earnings per share. research analysts anticipate that Foundation Medicine Inc will post -4.44 earnings per share for the current year.
A number of equities research analysts have weighed in on the company. BidaskClub downgraded Foundation Medicine from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Zacks Investment Research upgraded Foundation Medicine from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $45.33.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in FMI. Teachers Advisors LLC increased its holdings in shares of Foundation Medicine by 5.7% during the first quarter. Teachers Advisors LLC now owns 24,387 shares of the company’s stock valued at $786,000 after acquiring an additional 1,316 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Foundation Medicine by 5.2% during the first quarter. Vanguard Group Inc. now owns 583,496 shares of the company’s stock valued at $18,817,000 after acquiring an additional 28,619 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Foundation Medicine by 27.2% during the first quarter. Geode Capital Management LLC now owns 140,182 shares of the company’s stock valued at $4,520,000 after acquiring an additional 29,984 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Foundation Medicine by 5.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 54,823 shares of the company’s stock valued at $1,769,000 after acquiring an additional 2,736 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Foundation Medicine by 65.8% during the first quarter. Bank of America Corp DE now owns 6,180 shares of the company’s stock valued at $200,000 after acquiring an additional 2,452 shares in the last quarter. Hedge funds and other institutional investors own 33.44% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thelincolnianonline.com/2017/12/07/foundation-medicine-inc-fmi-director-evan-fa-jones-sells-6500-shares.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.